SCHEDULE: Vanguard Discloses 6.35% Stake in Tonix Pharmaceuticals
Beneficial Ownership Report (Schedule 13G)
The Vanguard Group has reported a 6.35% beneficial ownership stake in Tonix Pharmaceuticals Holding Corp. common stock.
Summary
- The Vanguard Group beneficially owns 556,957 shares of Tonix Pharmaceuticals Holding Corp. common stock.
- This ownership represents 6.35% of the total class of securities.
- Vanguard holds sole dispositive power over 496,907 shares and shared dispositive power over 60,050 shares.
- Vanguard holds shared voting power over 57,410 shares and no sole voting power.
- The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 6
Explanation: The disclosure of a significant institutional stake by Vanguard is generally viewed positively as it implies confidence, but it is a passive investment and does not provide operational or financial performance insights.
Positives
- Vanguard's significant 6.35% stake indicates institutional confidence in Tonix Pharmaceuticals.
- The passive nature of the investment, as stated, suggests a long-term, ordinary course holding rather than an activist position.
Future Outlook
NA
Industry Context
This filing reflects a standard institutional investment by a major asset manager, The Vanguard Group, in a pharmaceutical company. Such passive stakes are common and generally indicate inclusion in broad market index funds or actively managed portfolios, rather than a specific strategic move related to industry trends.
Stakeholder Impact
- Shareholders: May view Vanguard's stake as a vote of confidence, potentially stabilizing or positively influencing stock perception.
- Company Management: Awareness of a significant institutional holder like Vanguard may influence corporate governance considerations, though Vanguard states its stake is passive.
Key Dates
| Date | Description |
|---|---|
| 09/30/2025 | Date of event requiring the filing of this statement |
| 10/31/2025 | Signature date of the filing |
Keywords
Vanguard Group, Tonix Pharmaceuticals, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investment, Pharmaceuticals, Investment Adviser
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.